Zura Bio Ltd
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ZURA$1.41+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Three | ||||||
| · · Months Ended | ||||||
| · · March 31, | ||||||
| · 2024 · 2023 | ||||||
| Cash flows from operating activities · · · · | ||||||
| Net loss before redeemable noncontrolling interest | | $(7,747) | | $(9,795) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Anti-dilution share issuance compensation | | | — | | | 2,186 |
| Share-based compensation | | | 2,409 | | 180 | |
| Change in fair value of share-based payment liability | | | — | | 1,854 | |
| Change in fair value of note payable | | | — | | 2,244 | |
| Change in fair value of private placement warrants | | | 606 | | (177) | |
| Foreign exchange transaction (gain)/loss | | | (23) | | 9 | |
| Changes in operating assets and liabilities: | | | | | | |
| Prepaid expenses and other current assets | | | 380 | | (213) | |
| Accounts payable and accrued expenses | | | (607) | | 455 | |
| Net cash used in operating activities | | | (4,982) | | (3,257) | |
| Cash flows from investing activities | | | | | | |
| Purchase of property and equipment | | | (7) | | | — |
| Purchase of research and development license | | | (5,000) | | | — |
| Net cash used in investing activities | | | (5,007) | | — | |
| Cash flows from financing activities | | | | | | |
| Settlement of note payable | | | — | | | (10,000) |
| Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination | | | — | | 56,683 | |
| Payment of deferred transaction costs | | | — | | | (1,030) |
| Net cash provided by financing activities | | | — | | | 45,653 |
| Net (decrease)/increase in cash and cash equivalents | | | (9,989) | | | 42,396 |
| Cash and cash equivalents, beginning of period | | | 99,806 | | | 1,567 |
| Cash and cash equivalents, end of period | | $89,817 | | $43,963 | ||
| | | | | | | |
| Supplemental Disclosure | | | | | | |
| Cash paid for taxes | | | — | | | — |
| Cash paid for interest | | | — | | | — |
| | | | | | | |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities | | | | | | |
| Issuance of Series A-1 convertible preferred shares for license | | $— | | $— | ||
| Conversion of Series A-1 convertible preferred shares for Class A Ordinary Shares | | $— | | $14,686 | ||
| Adjustment of redeemable noncontrolling interest from redemption value to carrying value | | $7,017 | | $— | ||
| Purchase of property and equipment included in accounts payable and accrued expenses | | $2 | | $— | ||
| Assumption of public and private placement warrants in connection with Business Combination | | $— | | $3,715 | ||
| Reclassification of public warrant liability to equity | | $— | | $2,001 | ||
| Settlement of research and development license consideration liability | | $— | | $4,488 | ||
| Transaction costs included in accounts payable and accrued expenses | | $— | | $154 | ||
| Reclassification of deferred offering costs to additional paid-in capital | | $— | | $4,015 | ||
Zura Bio Limited
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.